

# Accepted Manuscript



Incidence of Esophageal Adenocarcinoma and Causes of Mortality After Radiofrequency Ablation of Barrett's Esophagus

W. Asher Wolf, Sarina Pasricha, Cary Cotton, Nan Li, George Triadafilopoulos, V. Raman Muthusamy, Gary W. Chmielewski, F. Scott Corbett, Daniel S. Camara, Charles J. Lightdale, Herbert Wolfsen, Kenneth J. Chang, Bergein F. Overholt, Ron E. Pruitt, Atilla Ertan, Srinadh Komanduri, Anthony Infantolino, Richard I. Rothstein, Nicholas J. Shaheen

PII: S0016-5085(15)01245-7  
DOI: [10.1053/j.gastro.2015.08.048](https://doi.org/10.1053/j.gastro.2015.08.048)  
Reference: YGAST 60008

To appear in: *Gastroenterology*  
Accepted Date: 20 August 2015

Please cite this article as: Wolf WA, Pasricha S, Cotton C, Li N, Triadafilopoulos G, Muthusamy VR, Chmielewski GW, Corbett FS, Camara DS, Lightdale CJ, Wolfsen H, Chang KJ, Overholt BF, Pruitt RE, Ertan A, Komanduri S, Infantolino A, Rothstein RI, Shaheen NJ, Incidence of Esophageal Adenocarcinoma and Causes of Mortality After Radiofrequency Ablation of Barrett's Esophagus, *Gastroenterology* (2015), doi: 10.1053/j.gastro.2015.08.048.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

All studies published in *Gastroenterology* are embargoed until 3PM ET of the day they are published as corrected proofs on-line. Studies cannot be publicized as accepted manuscripts or uncorrected proofs.

Incidence of Esophageal Adenocarcinoma and Causes of Mortality After Radiofrequency Ablation of Barrett's Esophagus

Short title: Adenocarcinoma and Mortality in Barrett's

W. Asher Wolf,<sup>1</sup> Sarina Pasricha,<sup>1</sup> Cary Cotton,<sup>1</sup> Nan Li,<sup>1</sup> George Triadafilopoulos,<sup>2</sup> V. Raman Muthusamy,<sup>3</sup> Gary W. Chmielewski,<sup>4</sup> F. Scott Corbett,<sup>5</sup> Daniel S. Camara,<sup>6</sup> Charles J. Lightdale,<sup>7</sup> Herbert Wolfsen,<sup>8</sup> Kenneth J. Chang,<sup>9</sup> Bergein F. Overholt,<sup>10</sup> Ron E. Pruitt,<sup>11</sup> Atilla Ertan,<sup>12</sup> Srinadh Komanduri,<sup>13</sup> Anthony Infantolino,<sup>14</sup> Richard I. Rothstein,<sup>15</sup> Nicholas J. Shaheen<sup>1</sup>

<sup>1</sup>From the University of North Carolina at Chapel Hill, Center for Esophageal Diseases and Swallowing, Division of Gastroenterology and Hepatology, Chapel Hill, NC; <sup>2</sup>Division of Gastroenterology and Hepatology, Stanford University School of Medicine; <sup>3</sup>Division of Digestive Diseases, David Geffen School of Medicine at UCLA; <sup>4</sup>Thoracic and Cardiac Surgery, Rush University Medical Center; <sup>5</sup>Gastroenterology Associates of Sarasota, Sarasota, FL, Florida Digestive Health Specialists; <sup>6</sup>Digestive Health Physicians, Cheektowaga, NY; <sup>7</sup>Division of Digestive and Liver Diseases, Columbia University; <sup>8</sup>Gastroenterology and Hepatology, Mayo Clinic; <sup>9</sup>Division of Gastroenterology, University of California, Irvine; <sup>10</sup>Gastrointestinal Associates, Knoxville, TN; <sup>11</sup>Nashville Gastrointestinal Associates, Nashville, TN; <sup>12</sup>Department of Medicine, University of Texas Health Medical School; <sup>13</sup>Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine; <sup>14</sup>Gastroenterology and Hepatology, Thomas Jefferson University Hospital; <sup>15</sup>Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center

Relevant Personal and Financial Disclosures: Dr. Shaheen receives research funding from Covidien Medical, CSA Medical, NeoGenomics, Takeda Pharmaceuticals, Interpace Diagnostics, and CDx Medical. He is a consultant for Oncoscope. Drs. Triadafilopoulos, Muthusamy, Chmielewski, Corbett, Camara, Lightdale, Wolfsen, Chang, Overholt, Pruitt, Ertan, Komanduri, Infantolino, and Rothstein have received research funding from Covidien Medical. Dr. Wolf has received funding to attend educational events sponsored by Nestlé. The other authors have no conflicts to declare.

This research was funded by T32 DK07634 and P30 DK034987 from the National Institutes of Health and GI Solutions, a subsidiary of Covidien.

Abbreviations: Barrett's esophagus (BE), complete eradication of intestinal metaplasia (CEIM), confidence interval (CI), endoscopic mucosal resection (EMR), esophageal adenocarcinoma (EAC), high grade dysplasia (HGD), indefinite for dysplasia (IND), low grade dysplasia (LGD), non-dysplastic Barrett's esophagus (NDBE), odds ratio (OR), person-years (PY), radiofrequency ablation (RFA)

Corresponding Author:

Nicholas J. Shaheen, MD, MPH  
Professor of Medicine and Epidemiology  
Director, Center for Esophageal Diseases and Swallowing  
University of North Carolina School of Medicine  
CB#7080  
Chapel Hill, NC 27599-7080  
Phone: (919) 966-2513  
Fax: (919) 843-2508

Download English Version:

<https://daneshyari.com/en/article/6093168>

Download Persian Version:

<https://daneshyari.com/article/6093168>

[Daneshyari.com](https://daneshyari.com)